Skip to main content
SpringerLink
Log in

The case for low-dose aspirin for the prevention of myocardial infarction: But how low is low?

  • Coronary Artery Disease
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Although there is firm consensus that aspirin reduces the incidence (and severity) of reinfarction if given to patients after a myocardial infarction or in patients with unstable angina, there is disagreement about the optimum dose that should be used. We make the case that it could be considerably lower than the “medium dose” (75–320 mg daily) in current usage and put forward the view that a dose of 30 mg daily is sufficient. The arguments are based on the presystemic, exclusively pharmacokinetic inhibition of thromboxane synthesis in platelets by very low-dose aspirin and the importance of maintaining prostacyclin production by endothelial cells. Little attention has been paid in the past to the endogenous myocardial protection that results from prostacyclin generation. Such low doses have the additional advantage of not inducing gastrointestinal ulceration. We conclude that more extensive clinical trials with such “low-dose” aspirin preparations are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fuster, V, Chesebro, JH. Aspirin for primary prevention of coronary disease. Eur Heart J 1986;16(Suppl E):16–20.

    Google Scholar 

  2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81–106.

    Google Scholar 

  3. The Dutch TIA Trial Study Group. A comparison on two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261–1266.

    Google Scholar 

  4. Underwood, MJ, More, RS. The aspirin papers. Aspirin benefits patients with vascular disease and those undergoing revascularisation. Br Med J 1994;308:71–72.

    Google Scholar 

  5. Parratt, JR. Endogenous myocardial protective (antiarrhythmic) substances. Cardiovasc Res 1993;27:693–702.

    Google Scholar 

  6. Vane, J, Botting, RM. A better understanding of antiinflammatory drugs based on isoforms of cyclooxygenase (COX-1 and COX-2). Adv Prostaglandin Thromboxane Leukot Res 1995;23:41–48.

    Google Scholar 

  7. Smith WL, Meade EA, DeWitt DL. Pharmacology of prostaglandin endoperoxide synthase isoenzymes-1 and-2. In: FitzGerald GA, Jennings LK, Patrono C, eds. Platelet-Dependent Vascular Occlusion. Ann NY Acad Sci 1994; 714:136–142.

  8. Henriksson, P, Wennmalm, A, Edhag, O, Versterqvist, O, Green, K. In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction. Br Heart J 1986;55:543–548.

    Google Scholar 

  9. Mueller, HS, Rao, PS, Greenberg, MA, et al. Systemic and transcardiac platelet activity in acute myocardial infarction in man: Resistance to prostacyclin. Circulation 1985;72: 1336–1345.

    Google Scholar 

  10. Bassenge, E. Control of coronary blood flow by autocoids. Basic Res Cardiol 1995;90:125–141.

    Google Scholar 

  11. Bunting, S, Moncada, S, Vane, JR. The prostacyclin-thromboxane A2 balance: Pathophysiological and therapeutic implications. Br Med Bull 1983;39:271–276.

    Google Scholar 

  12. Sinzinger, H, Virgolini, I, Peskar, BA. Response of thromboxane B2, malondialdehyde and platelet sensitivity to 3 weeks low-dose aspirin (ASA) on healthy volunteers. Thromb Res 1989;53:261–269.

    Google Scholar 

  13. Sinzinger, H, Silberbauer, K, Kaliman, J, Fitscha, P. 20 mg aspirin daily-evidence for a clinical future of this extremely low-dose in arterial disease?. Vasa 1988;17:10–15.

    Google Scholar 

  14. Knapp, HR, Healy, C, Lawson, J, FitzGerald, GA. Effects of low-dose aspirin on endogenous eicosanoid fomation in normal and atherosclerotic men. Thromb Res 1988;50:377–386.

    Google Scholar 

  15. De, Caterina, R, Gianessi, D, Bernini, W, et al. Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. Eur Heart J 1985;6:409–417.

    Google Scholar 

  16. Hoffmann, W, Förster, W. Two years Cottbus reinfarction study with 30 mg aspirin per day. Prostaglandins Leukot Essent Fatty Acids 1991;44:159–169.

    Google Scholar 

  17. Patrono, C, Ciabattoni, G, Patrignani, P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:1177–1184.

    Google Scholar 

  18. Montalescot, G, Maclouf, J, Drobinski, G, Salloum, J, Grosgogeat, Y, Thomas, D. Eicosanoid biosynthesis in patients with stable angina: Beneficial effects of very low dose aspirin. J Am Coll Cardiol 1994;24:33–38.

    Google Scholar 

  19. Keimwitz, R, McAdams, B, Maher, M, Fitzgerald, D. A dermal aspirin preparation (patch) with undetectable systemic bioavailability results in marked suppression of platelet cyclooxygenase (abstr). Circulation 1995;92(Suppl):2334.

    Google Scholar 

  20. Clarke, RJ, Mayo, G, Price, P, Fitzgerald, GA. Suppression of thromboxane A2 but not of systematic prostacyclin by controlled-release aspirin. N Engl J Med 1991;325:1137–1141.

    Google Scholar 

  21. FitzGerald, GA, Oates, JA. Selective and nonselective inhibition of thromboxane formation. Clin Pharmacol Ther 1984; 35:633–640.

    Google Scholar 

  22. Kallmann, R, Nieuwenhuis, HK, de, Groot, PG, van, Gijn, J. Sixma, JJ. Effects of low-dose aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1α excretion in healthy subjects. Thromb Res 1987;45:355–361.

    Google Scholar 

  23. Böger RH, Bode-Böger SM, Tsikas D, Frölich JC. Increased prostacyclin production during submaximal exercise in trained and untrained subjects: Effect of low-dose aspirin administration. Eur J Clin Pharmacol 1994;47:A94.

    Google Scholar 

  24. Hanley, SP, Bevan, J, Cockbill, SR, Heptinstall, S. Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet 1981;1:969–971.

    Google Scholar 

  25. FitzGerald, GA, Oates, JA, Hawiger, J, Maas, RL, Roberts, LJ, Lawson, JA, Brash, AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71:676–688.

    Google Scholar 

  26. Whittle, BJR, Moncada, S, Vane, JR. Some actions of prostacyclin (PG12) on the cardiovascular system and the gastric microcirculation. Acta Biol Med Germ 1978;37:725–728.

    Google Scholar 

  27. Coker, SJ, Parratt, JR. The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetised greyhounds. J Mol Cell Cardiol 1984;16:43–52.

    Google Scholar 

  28. Parrat, JR. Eicosanoids and arrhythmogenesis. In: Vaughan Williams, EM ed. Antiarrhythmic Drugs. Berlin: Springer, 1989:569–589.

    Google Scholar 

  29. Gryglewski, RJ. Interactions between nitric oxide and prostacyclin. Semin Thromb Hemost 1993;19:158–166.

    Google Scholar 

  30. Sinzinger, H, Grady, J, Fitscha, P, Kaliman, J. Extremely-low-dose aspirin (one milligram per day) renders human platelets more sensitive to antiaggregation prostagladins. N Engl J Med 1984;311:1052.

    Google Scholar 

  31. Förster, W. Prostaglandins and prostaglandin precursors as endogenous antiarrhythmic principles of the heart. Acta Biol Med Germ 1976;35:1101–1112.

    Google Scholar 

  32. Coker, SJ, Parratt, JR. Aspirin in the early stages of myocardial infarction. R. Soc Med Int Congr Symp Series No 1984; 71:71–75.

    Google Scholar 

  33. Parratt, JR, Coker, SJ, Wainwright, CL. Eicosanoids and susceptibility to ventricular arrhythmias during myocardial ischaemia and reperfusion. J Mol Cell Cardiol 1987;19 (Suppl 5):55–66.

    Google Scholar 

  34. Wainwright, C, Parratt, JR. Myocardial Preconditioning. Berlin: Springer, 1996.

    Google Scholar 

  35. Parratt, JR, Szekeres, L. Delayed protection of the heart against ischaemia. Trends Pharmacol Sci 1995;16:351–355.

    Google Scholar 

  36. Beitz, J Förster, W. Influence of human low density and high density lipoprotein cholesterol on the in vitro Prostaglandin 12 synthetase activity. Biochim Biophys Acta,1980; 620:352–355.

    Google Scholar 

  37. Förster, W, Beitz, J, Hoffmann, P. Stimulation and inhibition of PG12 synthetase activity by phospholipids (PL), cholesterol esters (CE), unesterified fatty acids (UFA) and lipoproteins (LDL and HDL). Artery 1980;8:494–500.

    Google Scholar 

  38. Giessler, Ch, Beitz, J, Mentz, P, Förster, W. The influence of lipoproteins (LDL and HDL) on PG12-formation by isolated aortic preparations of rabbits. Prostaglandins Leukot Med 1986;22:221–234.

    Google Scholar 

  39. Yui, Y, Aoyama, T, Morishita, H, Takahashi, M, Takatsu, Y, Kawai, C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I): A novel function of apo A-I. J Clin Invest 1988;82:803–807.

    Google Scholar 

  40. Kawai, C. Pathogenesis of acute myocardial infarction. Novel regulatory systems of bioactive substances in the vessel wall. Circulation 1994;9:1033–1043.

    Google Scholar 

  41. Sato, Y, Asaka, M, Takeda, H, Ohtaki, T, Miyazaki, T. The mechanism of aspirin-induced gastric mucosal injury. J Clin Gastroenterol 1993;17:S1-S4.

    Google Scholar 

  42. Whittle, BJR. Arachidonic acid metabolites and the gastrointestinal toxicity of anti-inflammatory agents. Prostaglandins 1981;21(Suppl):113–118.

    Google Scholar 

  43. Müller, P, Dammann, HG, Marinis, E, Simon, B. Gastroduodenale Verträglichkeit von 30 mg versus 300 mg Acetylsalicylsäure täglich. Med Klin 1990;85:429–431.

    Google Scholar 

  44. Müller, P, Damman, HG, Marinis, E, Simon, B. Endoskopische Untersuchungen zur gastroduodenalen Verträglichkeit 100 mg versus 500 Acetylsalicylsaure täglich: eine randomisierte Doppelblindstudie an gesunden Probanden. Z Gastroenterol 1989;27:418–420.

    Google Scholar 

  45. Nair, M, Sethi, KK. Low dose aspirin therapy in prophylaxis of cardiovascular disease—How low is low? Indian Heart J 1992;44:371–372.

    Google Scholar 

  46. Hoffmann, W, Förster, W. Zweijanresstudie an den Herzinfarkt-Patienten des Bezirkes Cottbus mit 30, 60 und 1000 mg Acetylsalicylsaure (ASS) je Tag-Einfluß auf Reinfarkt-Morbidität und Letalität. Z Klin Med 1987;42:2097–2101.

    Google Scholar 

  47. Förster, W. Reinfarkt-Prophylaxe mit niedrigdosierter ASS. Münch Med Wschr 1993;135:80–84.

    Google Scholar 

  48. Braun, M, Kramann, J, Strobach, H, Schrör, K. Incomplete inhibition of platelet secretion by low-dose aspirin. Platelets 1994;5:325–331.

    Google Scholar 

  49. Buerke, M, Pittroff, W, Meyer, J, Darius, H. Aspirin therapy-optimized platelet inhibition with different loading and maintenance doses. Am Heart J 1995;130:465–472.

    Google Scholar 

  50. Darius, H, Sellig, S, Belz, GG, Darius, BN, Aspirin 500 mg/d is superior to 100 and 40 mg/d for prevention of restenosis following PTCA. Circulation 1994;90(Suppl.):abst 3507.

    Google Scholar 

  51. Förster, W. Reinfarktoprophylaxe mit 100 mg oder 30 mg ASS täglich?. Z Kardiol 1995;84:335–343.

    Google Scholar 

Download references

Author information

Author notes

  1. Werner Förster (Professor Emeritus)

    Present address: , Schleiermacherstrasse 27, 06114, Halle (Saale), Germany

Authors and Affiliations

  1. Department of Physiology and Pharmacology, University of Strathclyde, Glasgow, Scotland

    Werner Förster (Professor Emeritus) & James Roy Parratt

Authors
  1. Werner Förster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Roy Parratt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Förster, W., Parratt, J.R. The case for low-dose aspirin for the prevention of myocardial infarction: But how low is low?. Cardiovasc Drug Ther 10, 727–734 (1997). https://doi.org/10.1007/BF00053030

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00053030

Key Words

Search

Navigation